<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442024000400109</article-id>
<article-id pub-id-type="doi">10.24875/rmn.23000078</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[12-year effectiveness and safety of botulinum toxin type A for the treatment of blepharospasm and hemifacial spasm]]></article-title>
<article-title xml:lang="es"><![CDATA[Eficacia y seguridad durante 12 años de la toxina botulínica tipo A para el tratamiento del blefaroespasmo y el espasmo hemifacial]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Colorado-Ochoa]]></surname>
<given-names><![CDATA[Héctor J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tenorio-González]]></surname>
<given-names><![CDATA[Victoria G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Neurología ]]></institution>
<addr-line><![CDATA[ Veracruz]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Medicina Interna ]]></institution>
<addr-line><![CDATA[ Veracruz]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2024</year>
</pub-date>
<volume>25</volume>
<numero>4</numero>
<fpage>109</fpage>
<lpage>114</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442024000400109&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442024000400109&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442024000400109&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: The objective of this study was to perform a long-term evaluation of the efficacy and safety of treatment with botulinum toxin A (BoNT-A) in patients with blepharospasm (BS) and hemifacial spasm (HFS) from January 2007 to December 2019.  Methods: In each application of BoNT-A, the date of treatment, number of units applied, and time elapsed since the previous application were recorded. Outcome data was: mean latency of the clinical effect, mean duration of the clinical effect, mean improvement on Jankovic rating scale, side effects were self-reported, and evaluated 2 weeks after injection, including non-responding patients to BoNT-A for two consecutive sessions. The comparison between the first and last dose of BoNT-A was analyzed by Student&#8217;s t-test, for which a value of p &lt; 0.05 was considered statistically significant.  Results: A total of 136 patients were analyzed; 60 had BS, 76 had HFS, and 75% were female. The duration between onset and referral for BoNT-A treatment was 18 ± 3 months, and the mean age at the time of the first therapeutic injection was 50 ± 12 years. The mean dose per session was 16 ± 4 for BS and 36 ± 12 for HFS. The therapeutic interval for injections was 4.4 ± 1 month. The mean latency of the clinical effect was 8 ± 3 days, the mean duration of the clinical effect was 112 ± 9 days, and the mean improvement on the Jankovic scale was 2 ± 1 points. Side effects were observed in 9 patients (6.6%), that is, ptosis (7 patients) and hematoma (2 patients).  Conclusions: BoNT-A is a safe and effective long-term treatment for BS and HFS.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Realizar una evaluación de largo plazo de la eficacia y seguridad del tratamiento con Toxina Botulínica A (BoNT-A) en pacientes con Blefaroespasmo y Espasmo Hemifacial entre Enero 2007 y Diciembre 2019.  Métodos: En cada aplicación de BoNT-A se registraron la fecha de tratamiento, número de unidades aplicadas, y el tiempo transcurrido desde la última aplicación. Los datos de desenlace fueron: el promedio de latencia del efecto clínico, el promedio de duración del efecto clínico, el promedio de mejoría en la Escala de Valoracion de Jankovic, los efectos secundarios fueron reportados por el paciente y evaluados 2 semanas después de la inyección, incluyendo pacientes no respondedores en 2 sesiones terapeúticas consecutivas. Las comparaciones de resultados entre la primera y la última dosis de BoNT-A fueron analizadas con la prueba t de Student, considerandose estadísticamente significativo un valor p &lt; 0.05.  Resultados: De un total de 136 pacientes analizados, 60 tenían blefaroespasmo, 76 tenían espasmo hemifacial, y 75% fueron femeninos, La duración entre el inicio y la referencia para tratamiento con BoNT-A fue de 18 ± 3 meses, la edad al momento de la primera inyección terapeútica fue de 50 ± 12 años de edad. El promedio de dosis por session fue 16 ± 4 en casos de blefaroespasmo, y 36 ± 12 en pacientes con espasmo hemifacial. El intervalo entre sesiones terapeúticas fue de 4.4 ± 1 meses. El promedio de latencia del efecto clínico fue de 8 ± 3 días, el promedio de duración del efecto clínico fue de 112 ± 9 días, y el promedio de mejoría en la Escala de Jankovic fue de 2 ± 1 puntos. Los efectos secundarios se observaron en 9 pacientes (6.6%) que presentaron ptosis (7 pacientes) y hematoma (2 pacientes).  Conclusiones: BoNT-A es segura y efectiva en la terapeutica de largo plazo en pacientes con blefaroespasmo y espasmo hemifacial.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Facial dystonia]]></kwd>
<kwd lng="en"><![CDATA[Blepharospasm]]></kwd>
<kwd lng="en"><![CDATA[Hemifacial spasm]]></kwd>
<kwd lng="en"><![CDATA[Botulinum toxin type A]]></kwd>
<kwd lng="es"><![CDATA[Distonía facial]]></kwd>
<kwd lng="es"><![CDATA[Blefaroespasmo]]></kwd>
<kwd lng="es"><![CDATA[Espasmo hemifacial]]></kwd>
<kwd lng="es"><![CDATA[Toxina botulínica tipo A]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bazaldúa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Colorado]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Granados]]></surname>
<given-names><![CDATA[victoria]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Espasmo hemifacial y blefaroespasmo]]></article-title>
<source><![CDATA[Rev Mex Neurosci]]></source>
<year>2009</year>
<volume>10</volume>
<page-range>78-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kenney]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin in the treatment of blepharospasm and hemifacial spasm]]></article-title>
<source><![CDATA[J Neural Transm (Vienna)]]></source>
<year>2008</year>
<volume>115</volume>
<page-range>585-91</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steeves]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dykeman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jette]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pringsheim]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence of primary dystonia:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2012</year>
<volume>27</volume>
<page-range>1789-96</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ababneh]]></surname>
<given-names><![CDATA[OH]]></given-names>
</name>
<name>
<surname><![CDATA[Cetinkaya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kulwin]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasm]]></article-title>
<source><![CDATA[Clin Exp Ophthalmol]]></source>
<year>2014</year>
<volume>42</volume>
<page-range>254-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Auger]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Whisnant]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemifacial spasm in rochester and olmsted County, Minnesota, 1960 to 1984]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>1990</year>
<volume>47</volume>
<page-range>1233-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Castelão]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sampaio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin type A therapy for blepharospasm]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>CD004900</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mejia]]></surname>
<given-names><![CDATA[NI]]></given-names>
</name>
<name>
<surname><![CDATA[Vuong]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term botulinum toxin efficacy, safety, and immunogenicity]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2005</year>
<volume>20</volume>
<page-range>592-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorgun]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Yilmaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Akin]]></surname>
<given-names><![CDATA[YA]]></given-names>
</name>
<name>
<surname><![CDATA[Mercan]]></surname>
<given-names><![CDATA[FN]]></given-names>
</name>
<name>
<surname><![CDATA[Akbostanci]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin injections for the treatment of hemifacial spasm over 16 years]]></article-title>
<source><![CDATA[J Clin Neurosci]]></source>
<year>2015</year>
<volume>22</volume>
<page-range>1319-25</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsiung]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Ranawaya]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lafontaine]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Suchowersky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2002</year>
<volume>17</volume>
<page-range>1288-93</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Czyz]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Petrie]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Watkins]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2013</year>
<volume>156</volume>
<page-range>173-7.e2</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bentivoglio]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Fasano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ialongo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Soleti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lo Fermo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Albanese]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fifteen-year experience in treating blepharospasm with Botox or Dysport:same toxin, two drugs]]></article-title>
<source><![CDATA[Neurotox Res]]></source>
<year>2009</year>
<volume>15</volume>
<page-range>224-31</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulinum toxin A injection in the treatment of hemifacial spasm]]></article-title>
<source><![CDATA[Acta Neurol Scand]]></source>
<year>1996</year>
<volume>94</volume>
<page-range>207-11</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cillino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Raimondi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guépratte]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Damiani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cillino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Pace]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion:a multicentre study using two drug-dose escalation indexes]]></article-title>
<source><![CDATA[Eye (Lond)]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>600-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jochim]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Meindl]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mantel]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zwirner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castrop]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of blepharospasm and Meige's syndrome with abo-and onabotulinumtoxinA:long-term safety and efficacy in daily clinical practice]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2020</year>
<volume>267</volume>
<page-range>267-75</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calace]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cortese]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Piscopo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Della Volpe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gagliardi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Magli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of blepharospasm with botulinum neurotoxin type A:long-term results]]></article-title>
<source><![CDATA[Eur J Ophthalmol]]></source>
<year>2003</year>
<volume>13</volume>
<page-range>331-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Streitová]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bare&#353;]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A:retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years]]></article-title>
<source><![CDATA[Acta Neurol Belg]]></source>
<year>2014</year>
<volume>114</volume>
<page-range>285-91</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gil Polo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Sanz]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Berrocal Izquierdo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Castrillo Sanz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez Ríos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zamora García]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blepharospasm and hemifacial spasm:long-term treatment with botulinum toxin]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2013</year>
<volume>28</volume>
<page-range>131-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramirez-Castaneda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia:a 20-year follow-up]]></article-title>
<source><![CDATA[Toxicon]]></source>
<year>2014</year>
<volume>90</volume>
<page-range>344-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
